<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2018-04-26" updated="2019-12-02">
  <drugbank-id primary="true">DB14017</drugbank-id>
  <name>H3B-8800</name>
  <description>H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine [L2551]. It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting [A32749]. H3B-8800 was granted orphan drug status by the FDA in August 2017 and is in clinical trials for the treatment of acute myelogenous leukemia and chronic myelomonocytic leukemia [L2551].</description>
  <cas-number>1825302-42-8</cas-number>
  <unii/>
  <average-mass>555.716</average-mass>
  <monoisotopic-mass>555.330836181</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A32749</ref-id>
        <pubmed-id>29457796</pubmed-id>
        <citation>Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, Agrawal AA, Caleb B, Csibi A, Sean E, Fekkes P, Karr C, Klimek V, Lai G, Lee L, Kumar P, Lee SC, Liu X, Mackenzie C, Meeske C, Mizui Y, Padron E, Park E, Pazolli E, Peng S, Prajapati S, Taylor J, Teng T, Wang J, Warmuth M, Yao H, Yu L, Zhu P, Abdel-Wahab O, Smith PG, Buonamici S: H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat Med. 2018 May;24(4):497-504. doi: 10.1038/nm.4493. Epub 2018 Feb 19.</citation>
      </article>
      <article>
        <ref-id>A32752</ref-id>
        <pubmed-id>27776121</pubmed-id>
        <citation>Fei DL, Motowski H, Chatrikhi R, Prasad S, Yu J, Gao S, Kielkopf CL, Bradley RK, Varmus H: Wild-Type U2AF1 Antagonizes the Splicing Program Characteristic of U2AF1-Mutant Tumors and Is Required for Cell Survival. PLoS Genet. 2016 Oct 24;12(10):e1006384. doi: 10.1371/journal.pgen.1006384. eCollection 2016 Oct.</citation>
      </article>
      <article>
        <ref-id>A32754</ref-id>
        <pubmed-id>21909114</pubmed-id>
        <citation>Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, Sato Y, Sato-Otsubo A, Kon A, Nagasaki M, Chalkidis G, Suzuki Y, Shiosaka M, Kawahata R, Yamaguchi T, Otsu M, Obara N, Sakata-Yanagimoto M, Ishiyama K, Mori H, Nolte F, Hofmann WK, Miyawaki S, Sugano S, Haferlach C, Koeffler HP, Shih LY, Haferlach T, Chiba S, Nakauchi H, Miyano S, Ogawa S: Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011 Sep 11;478(7367):64-9. doi: 10.1038/nature10496.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L2551</ref-id>
        <title>H3 Biomedicine Granted Orphan Drug Designation of H3B-8800 for Treatment of Acute Myelogenous Leukemia and Chronic Myelomonocytic Leukemia</title>
        <url>https://www.h3biomedicine.com/2017/08/14/h3-biomedicine-granted-orphan-drug-designation-of-h3b-8800-for-treatment-of-acute-myelogenous-leukemia-and-chronic-myelomonocytic-leukemia/</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics>H3B-8800 preferentially targets cells with spliceosome complexes containing mutant splicing factor 3B1 (SF3B1) protein, modulating intron splicing leading to increased death in cancer cells while having little effect on the viability cells with wild-type SF3B1 [A32749,A32752]. Both normal and aberrant mature mRNA are suppressed in mutant and wild-type cells, the selectivity of the lethal effect is thought to be due to the presence of mutant SF3B1 and its implications rather than a change in mechanism or potency of effect on the mutant protein over the wild-type [A32749 . Since SF3B1 is frequently mutated in cancer, this allows preferential targeting of cancer cells over host cells [A32754].</pharmacodynamics>
  <mechanism-of-action>H3B-8800 is thought to bind to a site similar to pladienolides on the SF3B complex within the spliceosome [A32749]. Once bound it induces increased retention of short (&lt;300 nucleotide) GC-rich introns through modulation of pre-mRNA processing. These intron-retained mRNA sequences are then thought to be destroyed through the nonsense-mediated decay pathway. It has been suggested that modulation by H3B-8800 is mediated by disruption of branchpoint sequence recognition by the SF3B complex as there is overall less preference for adenosine as the branchpoint nucleotide and a greater amount of sequences with weaker association to the SFB3 in introns retained with H3B-8800.&#13;
&#13;
It was found that 41 of 404 genes encoding spliceosome proteins contained GC-rich sequences whose retention was induced by H3B-8800 [A32749]. It is suggested that this is key to the specificity of H3B-8800's lethality as cells with spliceosome-mutant cells are dependent on the expression of wild-type spliceosome components for survival [A32752]. Since cancer cells, as in myelodysplasia, experience SF3B1 mutations much more frequently than host cells, this allows H3B-8800 to be used to preferentially target these cells by inducing intron-retention in critical spliceosome component pre-mRNA leading to destruction of the now nonsense mature RNA ultimately cell-death due to the lack of these critical proteins [A32749,A32754].</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms/>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories/>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.32</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.53e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.14</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(2S,3S,4E,6S,7R,10R)-7,10-dihydroxy-3,7-dimethyl-12-oxo-2-[(4E,6R)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl]-1-oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>(2S,3S,4E,6S,7R,10R)-7,10-dihydroxy-3,7-dimethyl-12-oxo-2-[(4E,6R)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl]-1-oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>555.716</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>555.330836181</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>C[C@H](\C=C\C=C(/C)[C@H]1OC(=O)C[C@H](O)CC[C@@](C)(O)[C@@H](OC(=O)N2CCN(C)CC2)\C=C\[C@@H]1C)C1=CC=CC=N1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C31H45N3O6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C31H45N3O6/c1-22(26-11-6-7-16-32-26)9-8-10-23(2)29-24(3)12-13-27(39-30(37)34-19-17-33(5)18-20-34)31(4,38)15-14-25(35)21-28(36)40-29/h6-13,16,22,24-25,27,29,35,38H,14-15,17-21H2,1-5H3/b9-8+,13-12+,23-10+/t22-,24+,25-,27+,29-,31-/m1/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>YOIQWBAHJZGRFW-WVRLKXNASA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>112.43</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>156.6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>62.34</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>13.92</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>6.89</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>71360838</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0009359</id>
      <name>Splicing factor 3B subunit 1</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A32756</ref-id>
            <pubmed-id>21981285</pubmed-id>
            <citation>Yokoi A, Kotake Y, Takahashi K, Kadowaki T, Matsumoto Y, Minoshima Y, Sugi NH, Sagane K, Hamaguchi M, Iwata M, Mizui Y: Biological validation that SF3b is a target of the antitumor macrolide pladienolide. FEBS J. 2011 Dec;278(24):4870-80. doi: 10.1111/j.1742-4658.2011.08387.x. Epub 2011 Oct 31.</citation>
          </article>
          <article>
            <ref-id>A32749</ref-id>
            <pubmed-id>29457796</pubmed-id>
            <citation>Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, Agrawal AA, Caleb B, Csibi A, Sean E, Fekkes P, Karr C, Klimek V, Lai G, Lee L, Kumar P, Lee SC, Liu X, Mackenzie C, Meeske C, Mizui Y, Padron E, Park E, Pazolli E, Peng S, Prajapati S, Taylor J, Teng T, Wang J, Warmuth M, Yao H, Yu L, Zhu P, Abdel-Wahab O, Smith PG, Buonamici S: H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat Med. 2018 May;24(4):497-504. doi: 10.1038/nm.4493. Epub 2018 Feb 19.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="O75533" source="Swiss-Prot">
        <name>Splicing factor 3B subunit 1</name>
        <general-function>Involved in pre-mRNA splicing as a component of the splicing factor SF3B complex (PubMed:27720643). SF3B complex is required for 'A' complex assembly formed by the stable binding of U2 snRNP to the branchpoint sequence (BPS) in pre-mRNA. Sequence independent binding of SF3A/SF3B complex upstream of the branch site is essential, it may anchor U2 snRNP to the pre-mRNA (PubMed:12234937). May also be involved in the assembly of the 'E' complex (PubMed:10882114). Belongs also to the minor U12-dependent spliceosome, which is involved in the splicing of rare class of nuclear pre-mRNA intron (PubMed:15146077).</general-function>
        <specific-function>Mrna binding</specific-function>
        <gene-name>SF3B1</gene-name>
        <locus>2q33.1</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>145829.085</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10768</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O75533</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SF3B1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Pre-mRNA-splicing factor SF3b 155 kDa subunit</synonym>
          <synonym>SAP 155</synonym>
          <synonym>SAP155</synonym>
          <synonym>SF3b155</synonym>
          <synonym>Spliceosome-associated protein 155</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0051617|Splicing factor 3B subunit 1
MAKIAKTHEDIEAQIREIQGKKAALDEAQGVGLDSTGYYDQEIYGGSDSRFAGYVTSIAA
TELEDDDDDYSSSTSLLGQKKPGYHAPVALLNDIPQSTEQYDPFAEHRPPKIADREDEYK
KHRRTMIISPERLDPFADGGKTPDPKMNARTYMDVMREQHLTKEEREIRQQLAEKAKAGE
LKVVNGAAASQPPSKRKRRWDQTADQTPGATPKKLSSWDQAETPGHTPSLRWDETPGRAK
GSETPGATPGSKIWDPTPSHTPAGAATPGRGDTPGHATPGHGGATSSARKNRWDETPKTE
RDTPGHGSGWAETPRTDRGGDSIGETPTPGASKRKSRWDETPASQMGGSTPVLTPGKTPI
GTPAMNMATPTPGHIMSMTPEQLQAWRWEREIDERNRPLSDEELDAMFPEGYKVLPPPAG
YVPIRTPARKLTATPTPLGGMTGFHMQTEDRTMKSVNDQPSGNLPFLKPDDIQYFDKLLV
DVDESTLSPEEQKERKIMKLLLKIKNGTPPMRKAALRQITDKAREFGAGPLFNQILPLLM
SPTLEDQERHLLVKVIDRILYKLDDLVRPYVHKILVVIEPLLIDEDYYARVEGREIISNL
AKAAGLATMISTMRPDIDNMDEYVRNTTARAFAVVASALGIPSLLPFLKAVCKSKKSWQA
RHTGIKIVQQIAILMGCAILPHLRSLVEIIEHGLVDEQQKVRTISALAIAALAEAATPYG
IESFDSVLKPLWKGIRQHRGKGLAAFLKAIGYLIPLMDAEYANYYTREVMLILIREFQSP
DEEMKKIVLKVVKQCCGTDGVEANYIKTEILPPFFKHFWQHRMALDRRNYRQLVDTTVEL
ANKVGAAEIISRIVDDLKDEAEQYRKMVMETIEKIMGNLGAADIDHKLEEQLIDGILYAF
QEQTTEDSVMLNGFGTVVNALGKRVKPYLPQICGTVLWRLNNKSAKVRQQAADLISRTAV
VMKTCQEEKLMGHLGVVLYEYLGEEYPEVLGSILGALKAIVNVIGMHKMTPPIKDLLPRL
TPILKNRHEKVQENCIDLVGRIADRGAEYVSAREWMRICFELLELLKAHKKAIRRATVNT
FGYIAKAIGPHDVLATLLNNLKVQERQNRVCTTVAIAIVAETCSPFTVLPALMNEYRVPE
LNVQNGVLKSLSFLFEYIGEMGKDYIYAVTPLLEDALMDRDLVHRQTASAVVQHMSLGVY
GFGCEDSLNHLLNYVWPNVFETSPHVIQAVMGALEGLRVAIGPCRMLQYCLQGLFHPARK
VRDVYWKIYNSIYIGSQDALIAHYPRIYNDDKNTYIRYELDYIL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0051618|Splicing factor 3B subunit 1 (SF3B1)
ATGGCGAAGATCGCCAAGACTCACGAAGATATTGAAGCACAGATTCGAGAAATTCAAGGC
AAGAAGGCAGCTCTTGATGAAGCTCAAGGAGTGGGCCTCGATTCTACAGGTTATTATGAC
CAGGAAATTTATGGTGGAAGTGACAGCAGATTTGCTGGATACGTGACATCAATTGCTGCA
ACTGAACTTGAAGATGATGACGATGACTATTCATCATCTACGAGTTTGCTTGGTCAGAAG
AAGCCAGGATATCATGCCCCTGTGGCATTGCTTAATGATATACCACAGTCAACAGAACAG
TATGATCCATTTGCTGAGCACAGACCTCCAAAGATTGCAGACCGGGAAGATGAATACAAA
AAGCATAGGCGGACCATGATAATTTCCCCAGAGCGTCTTGATCCTTTTGCAGATGGAGGG
AAAACCCCTGATCCTAAAATGAATGCTAGGACTTACATGGATGTAATGCGAGAACAACAC
TTGACTAAAGAAGAACGAGAAATTAGGCAACAGCTAGCAGAAAAAGCTAAAGCTGGAGAA
CTAAAAGTCGTCAATGGAGCAGCAGCGTCCCAGCCTCCATCAAAACGAAAACGGCGTTGG
GATCAAACAGCTGATCAGACTCCTGGTGCCACTCCCAAAAAACTATCAAGTTGGGATCAG
GCAGAGACCCCTGGGCATACTCCTTCCTTAAGATGGGATGAGACACCAGGTCGTGCAAAG
GGAAGCGAGACTCCTGGAGCAACCCCAGGCTCAAAAATATGGGATCCTACACCTAGCCAC
ACACCAGCGGGAGCTGCTACTCCTGGACGAGGTGATACACCAGGCCATGCGACACCAGGC
CATGGAGGCGCAACTTCCAGTGCTCGTAAAAACAGATGGGATGAAACCCCCAAAACAGAG
AGAGATACTCCTGGGCATGGAAGTGGATGGGCTGAGACTCCTCGAACAGATCGAGGTGGA
GATTCTATTGGTGAAACACCGACTCCTGGAGCCAGTAAAAGAAAATCACGGTGGGATGAA
ACACCAGCTAGTCAGATGGGTGGAAGCACTCCAGTTCTGACCCCTGGAAAGACACCAATT
GGCACACCAGCCATGAACATGGCTACCCCTACTCCAGGTCACATAATGAGTATGACTCCT
GAACAGCTTCAGGCTTGGCGGTGGGAAAGAGAAATTGATGAGAGAAATCGCCCACTTTCT
GATGAGGAATTAGATGCTATGTTCCCAGAAGGATATAAGGTACTTCCTCCTCCAGCTGGT
TATGTTCCTATTCGAACTCCAGCTCGAAAGCTGACAGCTACTCCAACACCTTTGGGTGGT
ATGACTGGTTTCCACATGCAAACTGAAGATCGAACTATGAAAAGTGTTAATGACCAGCCA
TCTGGAAATCTTCCATTTTTAAAACCTGATGATATTCAATACTTTGATAAACTATTGGTT
GATGTTGATGAATCAACACTTAGTCCAGAAGAGCAAAAAGAGAGAAAAATAATGAAGTTG
CTTTTAAAAATTAAGAATGGAACACCACCAATGAGAAAGGCTGCATTGCGTCAGATTACT
GATAAAGCTCGTGAATTTGGAGCTGGTCCTTTGTTTAATCAGATTCTTCCTCTGCTGATG
TCTCCTACACTTGAGGATCAAGAGCGTCATTTACTTGTGAAAGTTATTGATAGGATACTG
TACAAACTTGATGACTTAGTTCGTCCATATGTGCATAAGATCCTCGTGGTCATTGAACCG
CTATTGATTGATGAAGATTACTATGCTAGAGTGGAAGGCCGAGAGATCATTTCTAATTTG
GCAAAGGCTGCTGGTCTGGCTACTATGATCTCTACCATGAGACCTGATATAGATAACATG
GATGAGTATGTCCGTAACACAACAGCTAGAGCTTTTGCTGTTGTAGCCTCTGCCCTGGGC
ATTCCTTCTTTATTGCCCTTCTTAAAAGCTGTGTGCAAAAGCAAGAAGTCCTGGCAAGCG
AGACACACTGGTATTAAGATTGTACAACAGATAGCTATTCTTATGGGCTGTGCCATCTTG
CCACATCTTAGAAGTTTAGTTGAAATCATTGAACATGGTCTTGTGGATGAGCAGCAGAAA
GTTCGGACCATCAGTGCTTTGGCCATTGCTGCCTTGGCTGAAGCAGCAACTCCTTATGGT
ATCGAATCTTTTGATTCTGTGTTAAAGCCTTTATGGAAGGGTATCCGCCAACACAGAGGA
AAGGGTTTGGCTGCTTTCTTGAAGGCTATTGGGTATCTTATTCCTCTTATGGATGCAGAA
TATGCCAACTACTATACTAGAGAAGTGATGTTAATCCTTATTCGAGAATTCCAGTCTCCT
GATGAGGAAATGAAAAAAATTGTGCTGAAGGTGGTAAAACAGTGTTGTGGGACAGATGGT
GTAGAAGCAAACTACATTAAAACAGAGATTCTTCCTCCCTTTTTTAAACACTTCTGGCAG
CACAGGATGGCTTTGGATAGAAGAAATTACCGACAGTTAGTTGATACTACTGTGGAGTTG
GCAAACAAAGTAGGTGCAGCAGAAATTATATCCAGGATTGTGGATGATCTGAAAGATGAA
GCCGAACAGTACAGAAAAATGGTGATGGAGACAATTGAGAAAATTATGGGTAATTTGGGA
GCAGCAGATATTGATCATAAACTTGAAGAACAACTGATTGATGGTATTCTTTATGCTTTC
CAAGAACAGACTACAGAGGACTCAGTAATGTTGAACGGCTTTGGCACAGTGGTTAATGCT
CTTGGCAAACGAGTCAAACCATACTTGCCTCAGATCTGTGGTACAGTTTTGTGGCGTTTA
AATAACAAATCTGCTAAAGTTAGGCAACAGGCAGCTGACTTGATTTCTCGAACTGCTGTT
GTCATGAAGACTTGTCAAGAGGAAAAATTGATGGGACACTTGGGTGTTGTATTGTATGAG
TATTTGGGTGAAGAGTACCCTGAAGTATTGGGCAGCATTCTTGGAGCACTGAAGGCCATT
GTAAATGTCATAGGTATGCATAAGATGACTCCACCAATTAAAGATCTGCTGCCTAGACTC
ACCCCCATCTTAAAGAACAGACATGAAAAAGTACAAGAGAATTGTATTGATCTTGTTGGT
CGTATTGCTGACAGGGGAGCTGAATATGTATCTGCAAGAGAGTGGATGAGGATTTGCTTT
GAGCTTTTAGAGCTCTTAAAAGCCCACAAAAAGGCTATTCGTAGAGCCACAGTCAACACA
TTTGGTTATATTGCAAAGGCCATTGGCCCTCATGATGTATTGGCTACACTTCTGAACAAC
CTCAAAGTTCAAGAAAGGCAGAACAGAGTTTGTACCACTGTAGCAATAGCTATTGTTGCA
GAAACATGTTCACCCTTTACAGTACTCCCTGCCTTAATGAATGAATACAGAGTTCCTGAA
CTGAATGTTCAAAATGGAGTGTTAAAATCGCTTTCCTTCTTGTTTGAATATATTGGTGAA
ATGGGAAAAGACTACATTTATGCCGTAACACCGTTACTTGAAGATGCTTTAATGGATAGA
GACCTTGTACACAGACAGACGGCTAGTGCAGTGGTACAGCACATGTCACTTGGGGTTTAT
GGATTTGGTTGTGAAGATTCGCTGAATCACTTGTTGAACTATGTATGGCCCAATGTATTT
GAGACATCTCCTCATGTAATTCAGGCAGTTATGGGAGCCCTAGAGGGCCTGAGAGTTGCT
ATTGGACCATGTAGAATGTTGCAATATTGTTTACAGGGTCTGTTTCACCCAGCCCGGAAA
GTCAGAGATGTATATTGGAAAATTTACAACTCCATCTACATTGGTTCCCAGGACGCTCTC
ATAGCACATTACCCAAGAATCTACAACGATGATAAGAACACCTATATTCGTTATGAACTT
GACTATATCTTATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF08920</identifier>
            <name>SF3b1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>catalytic step 2 spliceosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear speck</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>spliceosomal complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>U11/U12 snRNP</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>U12-type spliceosomal complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>U2 snRNP</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>U2-type prespliceosome</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>mRNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mRNA splicing, via spliceosome</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of gene expression, epigenetic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>RNA splicing, via transesterification reactions</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>spliceosomal complex assembly</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>